Search
-
What Does It Mean to Participate in a Clinical Trial?
Participating in a clinical trial is voluntary and a personal choice. Clinical trials are research studies that involve people and are an important part of patient care. What is a clinical trial? Clinical trials are research studies that involve people, and they are an important part of patient care. There are several different types of clinical trials; some are designed to understand trends in a disease or identify better ways to diagnose a condition, while others determine if a new treatment is safe and works when treating, improving or preventing a health condition. There are over 400,000 clinical trials currently being conducted in the United States, and even more across the world. This includes health conditions such as heart failure, cancer, Parkinson’s Disease, respiratory conditions like COPD, common infections, cystic fibrosis, and many more. Clinical trials lead the healthcare industry to new discoveries that contribute to reliable and exact care, improving healthcare quality and saving lives. Clinical trials are conducted by a team of researchers, including doctors, pharmacists and clinical research coordinators. These research teams are highly skilled in their specialty areas, often providing traditional patient care and seeing research patients in the same day. These teams are responsible for making sure the clinical trial is completed correctly, and their patients are their top priority. Why should I consider participating in a clinical trial? Participating in a clinical trial is voluntary and a personal choice. There are many reasons why patients decide to get involved in clinical research. While many clinical trials are designed for patients who have a certain health condition, many studies also ask healthy volunteers to contribute in order to compare health outcomes. Clinical trials are also for patients at all different stages of their diagnosis. Depending on the specific study, the patient may receive access to a new cutting-edge treatment before it is widely available. When patients join a clinical trial, the research team becomes a health partner dedicated to their health and well-being. When patients join a clinical trial, they make an informed decision in their healthcare by weighing all available options in addition to routine treatments. Research participants know that they are contributing meaningfully and helping other patients like them. Where can I find more information about clinical trials at Renown Health? Renown Health’s mission is to make a genuine difference in the health and well-being of the communities we serve. Renown’s clinical trial portfolio offers leading care options to patients in northern Nevada, close to home, in a variety of specialties. Contact the Renown Clinical Research Office for more information on clinical trials available to you!
Read More About What Does It Mean to Participate in a Clinical Trial?
-
Top 5 Misconceptions About Clinical Trials
There are many misconceptions about clinical research, so we have unpacked a few common myths we hear to help you make an informed decision in your healthcare. Misconception #1: If I join a clinical trial, I’ll just be a guinea pig. Quite the opposite is true! Through honest and respectful conversation, we ensure all participants are informed of the benefits and risks associated with the clinical trial during the informed consent process. Being in a clinical trial is voluntary, and we respect our patients’ decision to join or decline to participate in the clinical trial. You can always change your mind at any time as well. When patients join a clinical trial, they receive an additional team of healthcare professionals, including additional physicians, pharmacists and research coordinators, dedicated to their safety and well-being. This means that clinical trial participants often receive more support than they would in the standard treatment setting. Misconception #2: Clinical trials are too dangerous because they use new treatments that haven’t been tested. We recognize that there are different levels of risk associated with participating in a clinical trial depending on the type of study. However, new treatments are only reviewed through clinical trials after they have gone through extensive testing. New treatments that do not show promising results for safety and potential benefit during laboratory testing do not receive approval to begin clinical trials. Your research team reviews any expected benefits and risks identified from previous studies during the informed consent process, as well as any updates that occur throughout the duration of the clinical trial. The research team stays in close contact with you during the entire process, documenting and treating any side effects that you experience for both your safety and the safety of participants like you. Misconception #3: I don't want to join a trial because I could be wasting my time receiving a placebo. A placebo is a substance that has no therapeutic effect, sometimes called a “sugar pill.” Participants who receive a placebo during a clinical trial are very important, helping researchers definitively determine the specific good and bad effects of the new medication. Many clinical trials that involve a placebo also offer what is called an open label extension or cross-over study. Cross-over studies ensure that anyone taking the placebo can begin receiving the new medication, often for several years. Cross-over studies help clinician researchers understand the long-term effects of a medication while also giving patients free access to novel care for several months and even years.
-
Governor Sisolak Signs Senate Bill 342
CARSON CITY, NV – Today, Nevada Governor Steve Sisolak signed Senate Bill 342 into law. The bill authorizes the Nevada System of Higher Education (NSHE) Board of Regents to enter into an agreement to affiliate with a publicly or privately- owned medical facility or related entity, whether for profit or not for profit, to further promote and enhance a medical education or health education program at a university. "Throughout the pandemic, we have relied on doctors, nurses and medical professionals to care for Nevadans in need. Legislation like this will help strengthen existing partnerships in the State so we can recruit, train and keep more medical professionals in Nevada,” said Gov. Sisolak. “I look forward to these continued partnerships to help our state for years to come.” Governor Sisolak was joined by University of Nevada Reno President and former Governor Brian Sandoval for the bill signing. “I wish to thank the members of the Nevada State Legislature and Governor Steve Sisolak for their support of this bill,” University of Nevada, Reno President Brian Sandoval said. “This collaborative and forward-thinking framework will provide cutting-edge patient care delivery, greater clinical research opportunities and will ensure that the next generation of medical providers in Nevada will receive the highest possible training. As the past year-plus has demonstrated, the health care environment in our state and throughout the country continues to be dynamic. The passage of this bill ensures that Nevada has the proactive tools to look to the future, so that we can meet our health care and medical education challenges.” “I appreciate and am so pleased that Governor Sisolak and the legislature approved Senate Bill 342 today, which provides support for integrating the University of Nevada, Reno School of Medicine with Renown Health,” said Anthony D. Slonim, MD, DrPH, FACHE, President and CEO, Renown Health, who was present at today’s signing. “This partnership will improve the health and healthcare of Nevadans and all of the communities that we serve. With this new level of affiliation, we will be able to drive innovation, research, medical education, grant funding for public health, clinical trials and integrate our medical practices to improve access and affordability of care. Together, we are excited to create a healthier Nevada.” “We are so appreciative of the unanimous support of the legislature and now the Governor’s signature and support of this bill that provides guidance to the NSHE Board of Regents as it considers the approval of this critical affiliation between UNR Med and Renown Health. We are excited to move to the next step of seeking approval from the Board of Regents for the affiliation and the establishment of an integrated health care system that will enhance medical care delivery and medical education, will improve health care, and will benefit the health and well-being of all Nevadans,” said University of Nevada, Reno School of Medicine Dean and Vice President, Health Sciences, Thomas L. Schwenk, M.D. “The opportunities to take medical care, medical education and clinical research in Nevada to an entirely new level are unlimited and we thank Governor Sisolak for moving us to the next step in this endeavor.” Photos from the bill signing can be requested from the Nevada Governor's Office. In addition, Governor Sisolak also signed the following bills today: Senate Bill 17 - Revises provisions governing the renewal of certain instruction permits to operate a motor vehicle or motorcycle. Senate Bill 23 - Revises the boundaries of the area from which certain members of the State Conservation Commission are appointed. Senate Bill 53 - Authorizes the Administrator of the Division of State Parks of the State Department of Conservation and Natural Resources to organize the areas under the jurisdiction of the Division into regions. Senate Bill 65 – Revises provisions relating to the composition and administration of the State Department of Agriculture. Nevada Governor's Office Public Relations Media Contact E: press@gov.nv.gov